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Edited by Richard MaraisAbstract CTCF is a transcription factor involved in various as-
pects of gene regulation. We previously reported that CTCF
function is modulated by protein kinase CK2. In this report we
investigate further the role of CK2 in regulating the transcrip-
tional properties of CTCF. We demonstrate that coexpression
of CTCF with CK2 switches function of CTCF from repressor
to activator. The non-phosphorylatable mutant increases repres-
sion by CTCF and potentiates the growth-suppressive ability of
the protein, whereas the phospho-mimetic mutant behaves in
the opposite fashion. Mutation of the individual serines reveals
that Serine 612 is a critical residue in regulation of CTCF by
CK2.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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CTCF is a highly conserved eleven zinc-ﬁnger (ZF) tran-
scription factor that has multiple DNA-binding sequence spec-
iﬁcity; its target sites have been characterised in the promoters,
silencers, insulators, and other regulatory regions of several
genes [1–7]. Depending on the promoter context and cell back-
ground, CTCF may repress [3,8–10] or activate [11] transcrip-
tion, however, its repression function predominates. CTCF
plays the paramount role in genomic imprinting [12,13] and
is involved in X-chromosome inactivation in mammals [14].
CTCF is a nuclear protein ubiquitously expressed in many
diﬀerent proliferating and diﬀerentiated cell types [2,3]. The
presence of the CTCF protein in many cell types raises the pos-
sibility that post-translational modiﬁcation could be a mecha-
nism controlling transcriptional properties of the universally
expressed CTCF protein. Our ﬁndings revealed that phosphor-Abbreviations: CTCF, CCCTC binding transcription factor; CK2,
protein kinase CK2; pCK2, catalytic a-subunit of protein kinase
CK2; pmCK2, kinase inactive mutant of the catalytic a-subunit of
protein kinase CK2; CAT, chloramphenicol acetyltransferase
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doi:10.1016/j.febslet.2005.01.044ylation by CK2 [15] and poly(ADP-ribosyl)ation [16] are the
mechanisms regulating the activity of CTCF post-translation-
ally. Phosphorylation proﬁle of CTCFwas found to be dynamic
depending on a given cell stage/line diﬀerentiation pathway [17].
A growing body of evidence also demonstrate that CTCF may
be involved in the TGFb signalling pathways [18,19].
Phosphorylation appears to be one the most important and
most studied form of post-translational modiﬁcations involved
in the regulation of transcription factor providing a link be-
tween signal transduction and expression of genes [20–22].
Phosphorylation controls the function of transcription factors
at diﬀerent levels. It can aﬀect, either positively or negatively,
DNA binding aﬃnity, trans-activating/-repressing function
or compartmentalisation of transcription factors [23,24].
Among the protein kinases, protein kinase CK2 (CK2), or for-
mer casein kinase II, is known for phosphorylation of proteins
involved in regulation of transcription, signalling, prolifera-
tion, various steps of development, metabolic processes and
also DNA repair [22,25,26]. CK2 is highly conserved in evolu-
tion and has been found in all eukaryotic cells investigated so
far [25]. CK2 is a dynamic molecular complex composed of
two subunits a and a 0 (representing the catalytic domain of
CK2) and a dimer of the b-subunits (representing the regula-
tory domain of CK2) [27,28]. It phosphorylates serines and
threonines immersed in acidic sequences within proteins and
peptides and the minimum requirement for phosphorylation
is the sequence S\/T\XXDE (in which asterisk denotes the
phosphorylated serine or threonine and X represents any
non-basic amino acid) [22]. In addition, the residue in the third
position towards the carboxyl end of the phosphorylatable
amino acid must be an acidic residue [29]; aspartic or glutamic
acid in this position can be replaced by phosphoserine [30].
In our previous report we mapped several functional protein
kinase CK2 phosphorylation sites within the C-terminal region
of CTCF, and demonstrated their importance for regulation of
CTCF by CK2. In this report we further investigate the func-
tional role of CK2 phosphorylation in the regulation of the
activity of CTCF. We demonstrate that coexpression of CTCF
with protein kinase CK2 change CTCF repressior function into
an activator function. Mutating all CK2 phosphorylatable res-
idues into non-phosphorylatable residues (phospho-ablation
mutant) or into acidic residues (phospho-mimetic mutant) gen-
erated proteins that did not respond to the exogenous CK2.
The phospho-ablation mutant increases the repression ten-
dency of CTCF in the context of the c-myc promoters, whereas,
the phospho-mimetic mutant of CTCF behaves as an activator.
Serine-612 has been identiﬁed as a critical residue in theblished by Elsevier B.V. All rights reserved.
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the phospho-ablation, but not phospho-mimetic, mutant of
CTCF potentiated the growth-suppressive ability of the wild-
type protein in COS 7 cells.2. Materials and methods
2.1. Generation of the CTCF mutants deﬁcient in CK2 phosphorylation
In order to investigate the role of CK2 in modiﬁcation of CTCF, ser-
ines matching the consensus site of CK2 (S\/T\XXDE) within the C-
terminal region of CTCF CS(578)GLDRS(604)KKEDS(609)S(610)
DS(612)EE . . .S(724)MMDR were mutated to generate the non-
phosphorylatable (phospho-ablation) CTCF and the acidic
(phospho-mimetic) mutants. The two-step PCR-mediated mutagene
procedure [31] was used to substitute serine residues with alanines/gly-
cines or glutamic acid. The external rightward primer carrying the
wild-type sequence was 5 0-ACTCAAAGTGGTACCATGAAGATG-
CAC-3 0, starting at nucleotide position 1707-bp of the CTCF cDNA
sequence, and harbouring consensus site for KpnI (underlined), num-
bered according to Klenova et al. [2]. The external leftward primer was
5 0-TCACCGGTCCATCATGCTGAGAATCAT-3 0, starting at nucleo-
tide position 2652 and encompassing consensus site for AgeI (under-
lined). For each mutant, two internal self-complementary (mutagenic)
primers were utilised (sequences are shown in brackets in the description
of the mutants below, mutated nucleotides are presented in bold).
The phospho-ablation CTCF mutants can be described as follows:
pAla604,609,610,612 (substituted Ser-604, 609, 610 and 612; 5 0(2261 bp)
ATGCGCGCTAAGAAAGAAGATGCCGGCGATGCTGAGGAA/
3 0-TACGCGCGATTCTTTCTTCTACGGCCGCTACGACTCCTT);
pAla578 (substituted Ser-578; 5 0(2181 bp)-GATAACTGTGCTGGCC-
TAGAT/30-CTATTGACACGACCGGATCTA); pAla604 (substituted
Ser-604; 5 0(2255 bp)-AGGAAGATGCGGCTAAG/30-TCCTTCTA-
CGCGCGATTC); pAla612 (substituted Ser-612; 5 0(2289 bp)-
GATGCTGAGGAAAATGCTGAA/3 0-CTACGACTCCTTTTACG-
ACTT); pAla604,612 (substituted Ser-604 and 612; 5 0(2261 bp)-
ATGCGCGCTAAGAAAGAAGATTCCTCCGATGCTGAGGAA/
3 0-TACGCGCGATTCTTTCTTCTAAGCAGGCTACGACTCCTT);
pAla578,604,609,610,612 (substituted Ser-578, 604, 609, 610 and 612) was
generated with the primer described for pA1a578 using the mutant
DNA of pAla604,609,610,612 as a template for ampliﬁcation. Finally,
the acidic (phospho-mimetic) mutant can be described as
pGlu604,609,610,612 (substituted Ser-604, 609, 610 and 612; 5 0(2261 bp)-
ATGCGCGAGAAGAAAGAAGATGAAGAAGATGAAGAGGAA/
3 0-TACGCGCTCTTCTTTCTTCTACTTCTTCTACTTCTCCTT).
To make pAla724 mutant (Ser-724 substituted with Ala), one-step
PCR was run with the rightward primer, starting at 1707-bp and car-
rying the wild-type sequence. The leftward primer carried mutated
bases (5 0(2651 bp)-ATGATTCTCGCCATGATGGACCGGTGA-
TGGAGG/TACTAAGAGCGGTACTACCTGGCCACTACCTCC);
and started at 2651-bp. The ampliﬁed products were puriﬁed, double
digested with KpnI and AgeI, and recloned into KpnI–AgeI sites within
backbone of the wild-type cDNA of CTCF expressing construct
(pCTCF) described previously [15]. The mutated variants of CTCF
were veriﬁed by sequencing.
2.2. Reporter and expression constructs
The expression construct pRC/CMV/(HA-CK2a) of the catalytic
a-subunit of protein kinase CK2 (abbreviated here as pCK2) and ki-
nase inactive CK2a K68M mutant (abbreviated here as pmCK2) were
provided by D. Litchﬁeld and previously described by Penner et al.
[32]. The chicken c-myc promoter-based construct, pPst2CAT, con-
tains the full-length promoter (3.2 kb) cloned upstream of the coding
region of the CAT reporter gene, and harbours a known CTCF bind-
ing site, FpV [1]. The reporter plasmid, p90TKCAT, was constructed
by ligating the dimeric CTCF binding site (synthetic 90 oligomer) from
the chicken c-myc promoter (219 to 180 bp) [(HindIII) 5 0-
AGCTTGAGCCCCTCGGCCGCCCCCTCGCGGCGCGCCCTCCC-
CGCACTAGTGAGCCCCTCGGCCGCCCCCTCGCGGCGCGCCC-
TCCCCGCT-3 0 (XbaI)] into the HindIII–XbaI site of the CAT vector,
pGLCAT4 [33] and termed pminCAT. The HindIII and XbaI sites
were created at the ends of the oligonucleotides to facilitate ligation
into pGLCAT4. The FPV (monomer binding site) is shown in italic.The pPst2(Nsi)CAT reporter carries a mutation in the CTCF-bind-
ing site [2]. A mutant version of the p90TKCAT deﬁcient for CTCF
binding (p90(Nsi)TKCAT), was made by ligating the mutant dimeric
(synthetic 90-bp oligomer) fragment, FpV(Nsi) [AGCTTGAGCCC-
CTCGGCCGCCCCCTATGCATGCGCCCTCCCCGCACTAGTG-
AGCCCCTCGGCCGCCCCCTATGCATGCGCCCTCCCCGCT]
into HindIII–XbaI sites of pGLCAT4 vector. The FPV (monomer
binding site) is shown in italic and the NsiI-mutation is shown in bold
italic. The SpeI site separating the two monomer CTCF binding se-
quences is underlined.
The albumin and adenovirus major late promoter-based constructs,
pAlb-CAT and pAd-MLP-CAT, respectively, were provided by
Dr. Nerlov and described in Nerlov and Ziﬀ [34]. The pGal4-CTCF is
a full-length CTCF cDNA fused, in frame, to the cDNA of the DNA-
binding domain of yeast transcription factor, Gal4, and the
p(6· UAS)TKCAT bears six copies of the Gal4 binding sites (UAS)
cloned upstream of pBLCAT2 reporter. There two vectors were kindly
provided byR.Renkawitz and L. Burke and described in Lutz et al. [35].
2.3. Cell culture and transfection procedure
COS 7 cells were maintained in Dulbeccos minimal essential medium
(DMEM) supplemented with 10% (v/v) fetal calf serum. DNA transfec-
tion was carried out by the standard calcium phosphate precipitation
method [36]. To monitor transfection eﬃciency, 50 ng of the plasmid
pRSV-b-Gal was used in all transfection experiments as an internal re-
porter control. Cells were harvested 48 h post-transfection and the
activities of chloramphenicol acetyltransferase (CAT) and b-galactosi-
dase were assayed as previously described. The CAT activities were
then normalised to the activities of b-galactosidase.2.4. Cell clonogenicity assay in COS7 cells
For stable transfection with CTCF mutants, the cells were plated (in
duplicate) at 1.5 · 106 per 10 cm plates containing 10 ml of DMEM
medium. Twenty-four hours post-plating, cells were cotransfected with
30 lg of expression constructs encoding CTCF mutants and 3 lg of
geneticin-resistant plasmid, pSV2neo. Twenty-four hours post-trans-
fection, the cells were trypsinised, and single cell suspension in fresh
medium was prepared. Cells were then re-seeded onto new plates in
diﬀerent dilutions, 0.75 · 106, 0.45 · 106, 1.5 · 105 and 0.75 · 105 cells
per plate. Forty-eight hours later, geneticin (Gibco-BRL), at ﬁnal con-
centration of 1 mg/ml, was added to media for selection. The cells were
maintained in selective medium for 18 days, during this time the selec-
tive medium was changed every 3 days. Selective medium contained
50% of fresh DMEM, 50% of the conditioned growth factor-enriched
medium and geneticin (1 mg/ml).
Cell labeling and immunoprecipitation were performed as reported by
Klenova et al. [15].
2.5. Western blotting
Proteins were resolved, transferred onto a membrane and probed as
described previously [37]. The primary antibodies used in this study
were the anti-CTCF polyclonal (Abcam) (1:300), the anti-a-CK2
polyclonal (gift from D. Litchﬁeld) (1:1000) and the anti-a-tubulin
monoclonal (Sigma) (1:500). The secondary anti-rabbit-peroxidase or
anti-mouse-peroxidase conjugated antibodies (Dako) were used at
1:10000 dilution. The antibodies were visualised by Enhanced Chemi-
luminescence as recommended by the supplier (Amersham).3. Results
CK2 relieves the transcriptional repression of the chicken
c-myc reporters mediated by CTCF. To investigate the func-
tional consequence of the phosphorylation of CTCF by CK2
in vivo, the catalytic a-subunit of CK2- and the chicken
CTCF-encoding constructs, pCK2 and pCTCF, respectively,
were co-expressed in COS7 cells. The cells were transfected
with 0.5 lg of either the chicken c-myc promoter-based CAT
reporter, pPst2CAT, or its mutated version pPst2(Nsi)CAT,
which is deﬁcient for CTCF binding, along with 1.0 lg of
pCTCF and increasing concentrations (1.0 and 2.0 lg) of
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was reported previously [32] and was conﬁrmed in our exper-
iments (Fig. 1D). No change in the levels of CTCF, endoge-
nous and exogenous, was noted upon the increasing
expression of CK2 (Figs. 1D and 2B). Nevertheless, as shown
in Fig. 1E, the exogenously supplied CK2 was able to eﬃ-
ciently phosphorylate CTCF.Fig. 1. CK2 relieves CTCF-dependent transcriptional repression activity of
COS7 cells were transfected with 0.5 lg of the chicken c-myc reporter, pPst
(bars with dotted ﬁlling) (A) or with 0.5 lg of the p90TKCAT (bars with st
ﬁlling) (C), together with the indicated concentrations (lg) of the shown const
on top of the ﬁgures. The results shown represent the mean values with the sta
experiment. The experiment was repeated ﬁve times. (B) Cotransfection exp
increasing concentrations of pCTCF and pCK2. DNA was balanced in all tr
post-transfection, total cell lysates were prepared, assayed for CAT activity a
CK2 is eﬃciently expressed in COS7 cells and CTCF levels do not alter upo
and anti-aCK2 (bottom) antibodies of the samples from transiently cotransfe
stripped and then probed with anti-aCK2 antibody. Numbers below show th
shown. (E) Cotransfection with pCK2 leads to CTCF phosphorylation in vivo
as indicated in the Figure. Cells were then metabolically labelled with [32P]or
previously described [15]. Protein samples were then resolved in 10% SDS–PA
same membrane was subsequently probed with the anti-CTCF antibodies (bCotransfection of both reporters with the empty vector,
pSG5, resulted in comparable transcriptional activities. In
the absence of CK2-encoding construct, the exogenous CTCF
inhibited expression of the wild-type reporter. However, 1.0 lg
of the pCK2 in the transfection mixture relieved this construct
from inhibition by the exogenous CTCF, and the increasing
dose of pCK2 progressively stimulated the activity of thethe chicken c-myc promoter and the minimal chicken c-myc promoter.
2CAT (bars with striped ﬁlling) or its mutant version, pPst2(Nsi)CAT
riped ﬁlling) or its mutant version, p90(Nsi)TKCAT (bars with dotted
ructs. Schematic map (not to scale) of the wild-type reporters are shown
ndard deviations (error bars) of triplicates in one typical cotransfection
eriments of 0.5 lg of the chicken pPst2CAT reporter along with the
ansfections with the parent expression vector, pSG5. Forty-eight hours
nd normalised to b-Gal activity as described in Section 2. (D) Ectopic
n CK overexpression: Western immunoblotting with anti-CTCF (top)
cted COS7 cells. Membrane was ﬁrst probed with anti-CTCF antibody,
e amount of the transfected vectors. Positions of CTCF and aCK2 are
. COS7 cells were cotransfected with the amount of pCTCF and pCK2
thophosphate, and CTCF was immunoprecipitated from the lysates as
GE, blotted onto a membrane and exposed to an X-ray ﬁlm (top). The
ottom). The position of CTCF is indicated.
Fig. 2. CK2 relieves transcriptional repression of the minimal
promoter-based reporter, 6 · UAS(TKCAT), mediated by the heter-
ologous protein, Gal4-CTCF. (A) COS7 cells were transfected with
0.5 lg of the p(6 · UAS)TKCAT along with the indicated concentra-
tions (lg) of the shown vectors. Schematic map (not to scale) of the
wild-type reporters are shown on top of the ﬁgure. Forty-eight hours
post-transfection, total cell lysates were prepared, assayed for CAT
activity and normalised to b-Gal activity as described in Section 2. The
results shown represent the mean values with the standard deviations
(error bars) of triplicates in one typical cotransfection experiment. The
experiment was repeated seven times. (B) Ectopic CK2 is eﬃciently
expressed in this experiment and levels of Gal4-CTCF and the
endogenous CTCF do not alter upon CK overexpression: Western
immunoblotting with anti-CTCF (top) and anti-aCK2 (bottom)
antibodies of the samples from transiently cotransfected COS7 cells.
Membrane was ﬁrst probed with anti-CTCF antibody, stripped and
then probed with anti-aCK2 antibody. Positions of Gal4-CTCF,
endogenous CTCF and CK2 are indicated. Numbers below show the
amount of the transfected vectors.
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crease in CAT expression from the mutant reporter, but much
less pronounced than that shown by the wild-type construct.
We then compared the expression patterns of pPst2CAT in-
duced by diﬀerent combinations of pCK2 and pCTCF concen-
trations. As the data in Fig. 1B show, in the context of the
chicken reporter, pPst2CAT, the eﬀects from pCK2 were more
pronounced with 1.0 and 2.0 lg of the pCTCF. The general
trend of the reporter namely, upregulation, with these doses
was essentially similar. Thus, 3.0 lg of pCK2 enhanced CAT
expression to 2.5- and 1.5-fold, respectively, over its basal le-
vel. Nonetheless, at 4.0 lg of the pCK2 transcription from
pPst2CAT was decreased, which could be an indirect eﬀect
(e.g., squelching) mediated by the pCK2. At higher doses of
pCTCF (3.0 and 4.0 lg), the plateau of repression emerged,
where the increasing doses of pCK2 did not relieve inhibition
by pCTCF.
To narrow down functional contribution of possible direct
or indirect activities of other transcription factors binding to
the pPst2CAT, the eﬀects of CK2 on CTCF were tested in
the context of the minimal promoter-driving reporter genes,
p90TKCAT and its mutated version, p90(Nsi)TKCAT. As
shown in Fig. 1C our observations using the natural c-myc
promoter-based reporter (pPst2CAT) were conﬁrmed in the
context of the minimal wild-type reporter, p90TKCAT. This
indicates that the increment of the expressed CAT level, from
both natural and minimal c-myc promoter-based reporters, is
very likely due to the speciﬁc eﬀect of CK2 on the CTCF.
Inability of pCK2 to stimulate transcriptional activity of the
mutant reporter, p90(Nsi)TKCAT, indicates that eﬀects of
the CK2 on the CTCF are dependent on the CTCF binding
to its cognate site.
Taken collectively, these experiments show that CK2
switches transcriptional inhibitory function of CTCF into an
activating mode, ultimately leading to the increase of basal
transcriptional activity from the chicken c-myc promoter.
CK2 relieves transcriptional repression activity of the chimeric
promoter-based reporter, p(6 · UAS)TKCAT, mediated by
Gal4-CTCF. To test that CK2 eﬀects on CTCF are direct in
the context of the designed promoter, a composite promoter-
based reporter, p(6 · UAS)TKCAT, and the hybrid, pGal4-
CTCF, were utilised. In these experiments, COS7 cells were
cotransfected with 0.5 lg of p(6 · UAS)TKCAT reporter to-
gether with 1.0, 2.0 and 3.0 lg of the pGal4-CTCF. As shown
in the Fig. 2A, the recruitment of CTCF into the vicinity of
transcriptional machinery of the TK promoter inhibits, in a
dose-dependent manner, the basal transcription of the reporter
gene. However, the introduction of pCK2 in a transfection
mixture converted repression tendency of pGal4-CTCF into
an activation mode, in a dose-dependent manner. Western blot
analysis conﬁrmed that this activation was indeed accompa-
nied by the increasing levels of CK2 (Fig. 2B). Lack of any
activity from the control assay (co-expression of the reporter
together with pGal424 and pCK2) supports the view that all
these activities are likely to be speciﬁc eﬀects of CK2 on the
CTCF protein.
Since there is no known mammalian protein with the same
consensus DNA-binding site as Gal4 [38], this assay is likely
to reﬂect the speciﬁc role of CK2 on CTCF, in the situation
when there is no interference with the endogenous CTCF pro-
tein. This is important since binding of the endogenous CTCF
phosphorylated by CK2 to its site in other natural (e.g.,pPst2CAT) or chimeric (e.g., p90TKCAT) promoter-based
construct may to some extent obscure the eﬀects of CK2 on
the ectopic CTCF.
The kinase inactive mutant, pmCK2, does not relieve tran-
scriptional repression mediated by CTCF. We next asked if
the eﬀects observed in our cotransfection experiments were in-
deed dependent on functional CK2. To address this question
we employed the kinase inactive CK2alpha K68M mutant
(pmCK2) in cotransfection experiments with pCTCF and
reporters p90TKCAT and p(6xUAS)TKCAT. As shown in
Figs. 3A and C, no eﬀects from pmCK2 were detected with
either reporter construct, although levels of expression from
Fig. 3. The kinase inactive mutant does not relieve transcriptional
repression mediated by CTCF. COS7 cells were transfected with 0.5 lg
of the p90TKCAT (A) or p(6xUAS)TKCAT (C) along with the
indicated concentrations (lg) of the shown vectors. Forty-eight hours
post-transfection, total cell lysates were prepared, assayed for CAT
activity and normalised to b-Gal activity as described in Section 2. The
results shown represent the mean values with the standard deviations
(error bars) of triplicates in one typical cotransfection experiment. The
experiment was repeated ﬁve times. (B) Levels of the expression of
CK2 and the kinase inactive mutant of CK2 correlate with the input of
the corresponding plasmids as shown byWestern immunoblotting with
the anti-aCK2 antibodies of the samples from transiently cotransfected
COS7 cells in the experiment described in (A). Position of CK2 is
indicated. Numbers below show the amount of the transfected vectors.
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series of experiments (Fig. 3B). Taking together, all the above
data demonstrate that phosphorylation of CTCF by CK2
plays an important role in regulating transcriptional activity
of the CTCF protein.
The phospho-ablation and phospho-mimetic mutants of CTCF
recapitulate transcriptional activities of the endogenous hypo-
and hyper-phosphorylated CTCF proteins, respectively, in the
context of the c-myc promoter constructs. Having established
that protein kinase CK2 relieved promoters from inhibition
by CTCF, we extended this line of research to gain further evi-
dence that all these activities are mediated by direct eﬀects of
CK2 on CTCF. For this purpose, the expression constructs
encoding a series of mutated CTCF derivatives at the CK2phosphorylatable residues were made. The phospho-ablation
and phospho-mimetic CTCF mutants were generated by
replacing potential CK2 phosphorylatable serine residues in
the C-terminal region with alanine/glycine and glutamic acid,
respectively (see Section 2 for detail). These mutant constructs
were based on the fact that substitution of the CK2 serines,
604, 609, 610 and 612, by non-phosphorylatable residues com-
pletely abolished the ability of CTCF to be phosphorylated in
vivo [15]. Two other residues, Ser-578 and Ser-724, were also
replaced by alanine residues. Although neither of these serines
were not shown to be phosphorylated in vivo in COS7 cells
[15], they are located within consensus motif of CK2 [22].
We reasoned that these sites might still be functional in other
cellular contexts and the individual mutants carrying substitu-
tions of these serines with alanine residues were also produced.
Some of the CTCF mutants harboured one substituted serine
residue, while others included diﬀerent combinations of the
replacements. Of note, substitution of serines by alanines/gly-
cine or glutamic acid did not alter localisation of these mutant
isoforms since all of them could be detected in the nucleus of
COS7 cells after transfection ([15] and data not shown).
The transcriptional properties of the CTCF mutants were
tested in the context of the chicken c-myc promoter-based re-
porter construct, pPst2CAT, and the results are summarised in
Fig. 4A. Expression constructs of the wild type and of the mu-
tants were cotransfected into COS7 cells in the increasing doses
(1.0, 2.0 and 3.0 lg). Levels of expression of the mutated vari-
ants were similar to the levels of the wild-type protein in the
transfected cells and proteins were produced according to con-
centrations of the corresponding expressing constructs (Fig.
4B).
In agreement with our previous observations [15], the CK2
site-deﬁcient mutant, pAla604,609,610,612, exerted a stronger
inhibitory inﬂuence than the wild-type CTCF protein-encod-
ing construct (pCTCF) at all three concentrations of the trans-
fected expressing vectors. Thus, while 1.0 lg of the wild-type
pCTCF reduced CAT level down to 75% of its basal activity,
this mutant repressed it down to 30% of the basal activity.
Addition of 2.0 lg of each expressing plasmid resulted in fur-
ther transcription repression down to 60% by the wild-type
protein and down to 25% by the pAla604,609,610,612; 3.0 lg of
the expressing constructs of pCTCF and pAla604,609,610,612
brought further reduction of the CAT level, which was much
more pronounced for the mutant protein.
Substitution of individual serines with alanines led to diﬀer-
ential response from the reporter, which ranged from repres-
sion to activation. Thus, single mutations of serines 578
(pAla578) and 604 (pAla604) created mutants that showed
repressor ability similar to the wild-type protein. On the other
hand, knocking out Ser-612 generated a repressor (pAla612)
that had a stronger inhibitory eﬀect on the reporter than the
wild-type protein. Mutation of two serines 604 and 612
(pAla604,612) did not potentiate, in additive manner, inhibitory
function of the single mutant, pAla612. Strikingly, one mutant,
pAla724, increased the constitutive activity of the reporter in a
dose-dependent manner. Substitution of ﬁve serines in the C-
terminal region led to a potent mutant (pAla578,604,609,610,612),
which inhibited expression of the reporter protein down to
25% of its basal level. On the other hand, the acidic mutant
of CTCF, pGlu604,609,610,612, behaved as a transcriptional acti-
vator in this assay. Although lower dose (1.0 lg) of this con-
struct did not promote basal CAT level, the highest dose
Fig. 4. The CK2 site-deﬁcient mutants of CTCF have distinct mode of action in the context of the chicken c-myc promoter. (A) COS7 cells were
transfected with 0.5 lg of the chicken c-myc reporter, pPst2CAT, along with the reported amounts (lg) of the shown constructs. Total DNA
concentrations were balanced in all experiments with the parent expression vector, pSG5. Forty-eight hours post-transfection, total cell lysates were
prepared, assayed for CAT activity and normalised to b-Gal activity as described in Section 2. The results shown represent the mean values with the
standard deviations (error bars) of triplicates in one typical cotransfection experiment. The experiment was repeated ﬁve times. (B) Western blot
showing levels of the CTCF proteins generated from the 1 (left) and 3 (right) lg of the following constructs: (1) pSG5, (2) pCTCF, (3)
pAla604,609,610,612, (4) pAla578, (5) pAla604, (6) pAla612, (7) pAla604,612, (8) pAla724, (9) Ala578,604,609,610,612 and (10) pGlu604,609,610,612.
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Thus, the presence of the constitutive negative charge at the
C-terminal region of CTCF obviated requirement for CK2.
Similar observations were made when a diﬀerent reporter,
p90TKCAT, was used in these experiments: each mutant reca-
pitulated its speciﬁc mode, which was observed in the context
of the natural c-myc promoter-based reporter (data not
shown). From these data we concluded that: (1) Ser-612,
appears to play the key role in the regulation of the chicken
c-myc promoter. (2) The four-site (pAla604,609,610,612) and
ﬁve-site (pAla578,604,609,610,612) mutants have pronounced tran-
scriptional repression functions, which may result from the
cumulative eﬀect of single serines. (3) The data showing that
knocking out Ser-724 created the CTCF protein with features
of an activator indicate that complex combinatorial eﬀects of the
phosphoacceptor sites regulate CTCF transcription properties.
Transcriptional behaviour of CTCF mutants is speciﬁc to
CTCF-dependent promoters. This line of research was contin-
ued to test transcriptional properties of the CTCF mutants
in the contexts of other promoters, not known to be CTCF-
responsive targets. In these experiments, cotransfection of
1.0, 2.0 and 3.0 lg of each of the wild type, pAla604,609,610,612
and pGlu604,609,610,612 along with pAlb-CAT, the albumin pro-
moter-driving CAT, did not alter basal CAT level of this re-
porter construct. As shown in Fig. 5B, proteins were
produced according to concentrations of the corresponding
expressing constructs. Similar results were obtained when an
adenovirus-major late gene promoter fused to the CAT gene,
pAdMLP-CAT, was used as a reporter in cotransfection
experiments (data not shown). Taken together, these observa-
tions suggest that eﬀects of the CK2 site-deﬁcient mutants of
CTCF are speciﬁc to the CTCF-dependent promoters, and
that replacing Ser with Ala/Gly residues did not create fortu-
itously a constitutive transcriptional repressor.Exogenous CK2 does not relieve repression of the chicken
c-myc reporter constructs induced by the CTCF mutants,
pAla604,609,610,612, pAla578,604,609,610,612, pAla612 and pAla604,612.
To test the eﬀects of the ectopic CK2 on the speciﬁc behaviour
of the phopshorylation deﬁcient CTCF variants in the context
of the chicken c-myc promoter, COS7 cells were transfected
with 1.0 lg of each of CTCF mutants along with the increasing
concentrations (0.0, 1.0, 2.0, 3.0 and 5.0 lg) of pCK2. The
equivalent expression of the proteins from each expressing
construct was conﬁrmed by Western analysis (Fig. 6B). As
shown in Fig. 6A, the wild-type construct, pCTCF, exhibited
a typical dose-dependent response to pCK2. On the other
hand, non-phosphorylatable mutants, which imposed stronger
inhibitory role than that of the wild-type protein on the repor-
ter (Fig. 4A), resisted stimulating action of the pCK2. This can
be demonstrated with the pAla604,609,610,612 and
pAla578,604,609,610,612 mutants. On the other hand, the single
mutants such as pAla578 and pAla604, which exhibited wild-
type protein-inhibitory ability (Fig. 4A), showed positive re-
sponse to pCK2 comparable to the wild-type vector. The single
(pAla612) and double (pAla604,612) mutants did not show any
signiﬁcant response to CK2. However, the highest dose of
the pCK2 (5.0 lg) had positive eﬀect, which could be due to
indirect eﬀect of the kinase. Strikingly, one mutant, pAla724,
exhibited negative response to the pCK2, in a dose-dependent
manner. Finally, the acidic mutant, pGlu604,609,610,612, also re-
sisted the eﬀect of pCK2.
The eﬀects of CK2 on the mutant proteins observed in the
context of the natural c-myc promoter, pPst2CAT were reca-
pitulated in the context of the p90TKCAT minimal promoter
(data not shown).
Taking all these data collectively, we conclude that (1) the
CK2 did not relieve inhibitory eﬀect of pAla604,609,610,612,
pAla612, pAla604,612 and pAla578,604,609,610,612, in the contexts
Fig. 5. The wild-type phospho-ablation and phospho-mimetic mutants of CTCF do not alter the basal transcription activity of the albumin (Alb)
promoter-based reporter. (A) COS7 cells were transfected with 0.5 lg of the albumin pAlb-CAT promoter-based vector along with reported
concentrations (lg) of the wild type, and phopsho-ablation (pAla604,609,610,612) and phospho-mimetic (pGlu604,609,610,612) mutants of the CTCF and
the empty vector, pSG5. Forty-eight hours post-transfection, total cell lysates were prepared, assayed for CAT activity and normalised to b-Gal
activity as described in Section 2. The results shown represent the mean values with the standard deviations (error bars) of triplicates in one typical
cotransfection experiment. The experiment was repeated ﬁve times. (B) Western blot of the samples from this experiment shows the levels of the
CTCF proteins generated from the 1, 2 and 3 lg of the wild-type CTCF and mutant constructs. The position of CTCF is indicated.
Fig. 6. Eﬀects of CK2 phosphorylation-deﬁcient mutants of CTCF cotransfected with CK2 on the chicken c-myc promoter constructs. (A) COS7
cells were transfected with 0.5 lg of the chicken natural c-myc promoter-based reporter, pPst2CAT, 1.0 lg of the reported CTCF expressing vectors
together with 0.0, 1.0, 2.0, 3.0 and 5.0 lg, respectively, of CK2-expressing construct. Total DNA concentration was balanced in all experiments with
the parent expression vector, pSG5. Forty-eight hours post-transfection, total cell lysates were prepared, assayed for CAT activity and normalised to
b-Gal activity as described in Section 2. The results shown represent the mean values with the standard deviations (error bars) of triplicates in one
typical cotransfection experiment. The experiment was repeated ﬁve times. (B) Western blot showing levels of the CK2 protein generated from the 1
(left) and 3 (right) lg after co-transfection with 1 lg the following constructs: (1) pSG5, (2) pCTCF, (3) pAla604,609,610,612, (4) pAla578, (5) pAla604, (6)
pAla612, (7) pAla604,612, (8) pAla724, (9) Ala578,604,609,610,612 and (10) pGlu604,609,610,612.
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able to activate pAla578 and pAla604 mutants.
The phopsho-ablation mutant of CTCF suppresses cell growth
of COS7 cells more eﬃciently than the wild-type CTCF. Ectopic
expression of CTCF in many cell types inhibited cell clonoge-
nicity by causing profound growth retardation [39]. In this re-
port, we demonstrated that dephosphorylated CTCF mutant
(pAla604,609,610,612) exerted stronger inhibitory function than
the wild-type protein on the c-myc promoter. As the c-myc
gene is one of the prominent proliferation-controlling genes,
we then asked if the substitution of the serine residues in the
C-terminus of CTCF would interfere with the ability of CTCF
to suppress the proliferative potential of COS7 cells.
For this purpose, COS7 cells were stably transfected with the
plasmids expressing individual CTCF mutants and the vector
pSV40neo containing a neomycin resistance gene. At the
10:1 ratio between these plasmids all the neomycin resistant
cells were presumed to contain the CTCF-expressing plasmid.
A control pSG5 plasmid that does not express CTCF was also
exploited to establish the basal focus-forming potential of cells
in the absence of any exogenous CTCF isoform. Twenty-four
hours post-transfection, cells were subjected to G418 selection
and two weeks later the number of colonies was counted. Ten
independent colonies from each transfection were picked,
mixed and expanded. The cells were then collected, lysed and
the Western assay performed. As shown in Fig. 7B, the levels
of the exogenous CTCF (wild type and mutated) expressed in
these cells are comparable.Fig. 7. Eﬀects of mutations of the CK2 phosphorylation sites on the
ability of CTCF to suppress growth of COS7 cells. (A) COS7 cells were
stably cotransfected with 3.0 with the indicated expression constructs
and selected with G418 as described in Section 2. In some plates
(pSV2neo-free), cells were cotransfected with pSG5 without the G418
resistant plasmid, pSV2neo. The 100% value was assigned to the
numbers of colonies formed with the pSG5 control vector. The error
bars indicate standard deviation of four independent transfections with
each expression vector. (B) Western blot showing levels of the CTCF
proteins generated from the lysates of 10 individual colonies collected
and expanded from the stable transfection experiments with the
following nine vectors: (1) pSG5, (2) pCTCF, (3) pAla604,609,610,612, (4)
pAla578, (5) pAla 604, (6) pAla612, (7) pAla604,612, (8) Ala578,604,609,610,612
and (9) pGlu604,609,610,612. 20 lg of the total protein was used in this
experiment. Equal loading was conﬁrmed by re-probing the membrane
with the anti-a-tubulin antibodies. Positions of CTCF and a-tubulin
are indicated.The results of multiple assays for each mutant of CTCF are
summarised in Fig. 7A. Colony formation of the transfectants
was dependent in the presence of the pSV2neo plasmid since
there was no cell growth in the absence of pSV2neo plasmid.
The wild-type CTCF suppressed the number of growing foci
down to 67% (the control vector pSG5 is taken as 100%).
The substitution of alanines/glycines for any single serine did
not signiﬁcantly increase suppression eﬃciency of CTCF. Sub-
stitution of four or ﬁve serines, however, decreased the number
of colonies to 35% for pAla604,609,610,612 and 40% for
pAla578,604,609,610,612. The acidic mutant of CTCF,
pGlu604,609,610,612 exhibited the opposite eﬀect, relieving
growth suppression activity of the wild-type CTCF. Thus,
the eﬀects of only the phospho-ablation and phospho-mimetic
CTCF mutants in the colony-formation assay paralleled their
functional roles in the context of c-myc promoter-based
reporters.4. Discussion
This work extends our previous study on regulation of a
transcription factor, CTCF, by phosphorylation with protein
kinase CK2 [15] providing further evidence about the func-
tional signiﬁcance of this post-translational modiﬁcation of
CTCF. We demonstrated that cotransfection of CTCF and
CK2 switched the function of CTCF, in the context of the
chicken c-myc promoter, from a transcriptional repressor to
an activator. This transition depends on modiﬁcation of CTCF
by CK2, because (i) both natural and chimeric chicken c-myc
promoter-based constructs exhibited progressive activation,
which was dependent on the levels of CK2 and was more pro-
nounced in the presence of the exogenous CTCF; (ii) these ef-
fects were CTCF-target site dependent since co-expression of
pCTCF and pCK2 together with the reporter constructs bear-
ing the CTCF-mutated site [pPst2(Nsi)CAT and p90(Nsi)TK-
CAT] insigniﬁcantly activated basal expression of the
reporters, (iii) the kinase-inactive mutant of CK2 had no eﬀect
in these assays and, ﬁnally, (iv) repression by the Gal-4-CTCF
protein from the composite promoter-based reporter,
p(6 · UAS)-TKCAT was found to be eﬃciently relieved by
CK2. In addition, selective inhibitors of CK2 such as apigenin
[40] and 5,6-dichloro-1-b-D-ribofuranosylbenzimidazole
(DRB) [41] abolished the activating inﬂuence of CK2 (E. Kle-
nova, personal communication).
Studies on the CTCF mutants provided a further link be-
tween modiﬁcation of CTCF by CK2 and activation of the
chicken c-myc reporter constructs. It was previously shown
that phosphorylation residues in CTCF are restricted to the
motif spanning Ser-604 to 612 (18). In the contexts of all
the c-myc promoter-based constructs, substitution of all ser-
ines, 604, 609, 610 and 612, with Ala created the CTCF iso-
forms (e.g., pAla604,609,610,612 and pAla578,604,609,610,612) that
exerted stronger inhibitory eﬀects than the wild-type protein.
This observation supports the model that activation of
c-myc promoters induced by synergistic action of CTCF and
CK2 is directly mediated by phosphorylation of CTCF at
Ser-604/609/610/612. Furthermore, the pAla604,609,610,612,
pAla578,604,609,610,612 and pGlu604,609,610,612 mutants consis-
tently resisted the eﬀects of pCK2 in the contexts of all c-
myc reporters, which implies that CK2 modiﬁes the wild-type
protein at those residues in vivo. The pAla604 and pAla578 had
1432 A. El-Kady, E. Klenova / FEBS Letters 579 (2005) 1424–1434wild-type protein-like response to CK2 conﬁrming that Serine-
604 and Serine-578 are not critical for CTCF function.
Although the panel of CK2 phosphorylation deﬁcient mutants,
which was generated and tested in this report is not compre-
hensive, we provide evidence that Serine-612 has a critical role
in regulation of the transcriptional function of CTCF because
pAla612 had functional abilities comparable with the
non-phopshorylatable pAla604,609,610,612 mutant. The impor-
tance of Ser-612 might have been attributed to its role as a
‘‘gate-keeper’’ in controlling phosphorylation of other up-
stream residues (e.g., Serines 604, 609 and 610). Further tests
revealed that phopshorylation of CTCF does not occur when
Ser-612 is mutated (data not shown) and this mutant was resis-
tant to the ectopic CK2 (Fig. 6). It is conceivable that phosphor-
ylation at this site may be suﬃcient to induce a particular
conformation that is critical for the assembly of the functional
protein associations involved in control of cellular functions.
As known from the literature, phosphorylation of BAD at a sin-
gle Ser-136 promotes association with 14-3-3 proteins [42]
which results in its sequestering from the apoptotic machinery.
The substitution of Ser-724 into Alanine generated a CTCF
mutant (pAla724) that activated chicken c-myc promoter in
COS7 cells. This result was surprising since Ser-724 was not
found to be phosphorylated in COS7 cells in vivo [15]. The
trivial explanation may be that this mutation generated a for-
tuitous protein with structural changes possibly resembling the
phospho-mimetic mutant of CTCF. It is however possible that
association with other proteins (e.g., Yb-1 or B23 [37,43] and
others) or even with another molecule of CTCF [44] could pro-
tect Ser-724 from phosphorylation. Similar situations have
been described in the literature. For example, p67 interaction
with eIF2a protects the latter from phosphorylation [45]; like-
wise, association of replication factor C with PCNA conceals
the phosphorylation sites on the PCNA molecule [46]. Another
explanation for such discrepancy could be that the phosphate
at the Ser-724 is particularly eﬃciently removed by serine/thre-
onine protein phosphatases, for example PP2A [47].
The introduction of the negative charge at the phosphoryla-
tion sites by replacement of the serines (604, 609, 610 and 612)
with the glutamic acid residues created a phopsho-mimetic
CTCF mutant that stimulated all c-myc reporters (particularly
at higher doses). This observation demonstrates that the pres-
ence of the constitutive negative charge carried by this mutant
compensated requirement for CK2. Nonetheless, the inherent
transcriptional activating role of this acidic mutant is weaker
than that mediated by synergistic action of the wild-type pro-
tein and CK2. This could be due to the weak negative charge
of the carboxylate group of the glutamic acid, which can not
exclusively emulate functional role of phosphate moiety in
the phosphorylated CTCF isoform. However, overexpression
of this ‘‘weak’’ acidic mutant at higher levels (3.0 lg) compen-
sated for the partial weakness of its charge. Thus, the ability of
CTCF to change the mode of action depending on its phos-
phorylation status may shed light into its ability to function
as a repressor or activator depending on cellular and promoter
context [4,5].
In this study we also tested whether the substitutions of the
CK2 sites could aﬀect cell growth inhibition by CTCF. The ob-
tained results show that the growth suppressive eﬀects of the
wild-type CTCF in COS7 were signiﬁcant, but not very strong.
Such a response may depend on cell type as our previously re-
ported observations showed [39]. After transfection with thewild-type CTCF, HeLa, K562 and Raji cells demonstrated a
reduction of colonies to 30–40% compared to 5–10% in other
cell lines (PC3, 293 and HD3) [15,39]. In this report we ob-
served that the substitution of four and ﬁve serines in
pAla604,609,610,612 and pAla578,604,609,610,612 caused remarkable
growth inhibition (Fig. 7). These results contradict our previ-
ous ﬁnding showing the release from repression in HD3 and
PC3 cells by the phospho-ablation mutant [15]. It should how-
ever be noted that the CK2 phosphorylation sites were initially
mapped in COS7 cells and therefore the function of CK2
phosphorylation may be reﬂected more accurately in the con-
text of COS7 cells. Cellular context indeed may be a signif-
icant factor in determining the mode of action of a protein
since diﬀerent kinases and interacting proteins may be in-
volved in regulation of its function as, for example, is though
to be the case for the retinoblastoma tumor suppressor
protein, pRb [48].
Although the eﬀects of the mutants carrying single or double
substitution of serines on the c-myc promoter were apparent,
these mutants failed to alter signiﬁcantly the cell growth-sup-
pression abilities of the wild type CTCF protein. This is how-
ever not surprising because CTCF controls transcriptional
activity of many genes involved in the regulation of cell prolif-
eration including p19ARF, polo-like kinase (PLK), Igf2 and
others [4,5,19,49]. Thus, suppression or activation of cell pro-
liferation may require a threshold of positive or negative
charges carried by CTCF to have an impact on various genes
regulated by CTCF, which may not be achieved at the level of
single mutation. Cumulative eﬀects mediated by mutating sev-
eral serines have been also observed by other proteins, for
example p53 protein. Single substitution of serine-9, 17 or 37
with alanine in p53 N-terminus did not alter growth-suppres-
sion ability of the wild-type p53, however, altering all serines
(9, 17 and 37) to alanines produced remarkable eﬀect on cell
growth [50,51].
Thus, our observations provide further evidence that the
phosphorylation status of CTCF has critical consequences
on cell physiology, where either arrest of cell growth or induc-
tion of cell proliferation is required; deregulated phosphoryla-
tion levels of CTCF may uncouple these biological activities in
one way or another. The intriguing question in this model is
how the activation and repression of CTCF can be modulated
by CK2 phosphorylation if this enzyme is known to be consti-
tutively active [52]? Indeed this is a general question that re-
lates to more than 160 substrates of CK2 [53]. The current
understanding of CK2 regulation is that its activity may be
controlled by mechanisms that do not involve receptors and
second messengers, but rely on the change in CK2 localisation
in the cell, modulation of CK2 levels, associations with protein
partners, activity of phosphatases, eﬀects of substrate and oth-
ers ([53] and references therein). CTCF, as one of the sub-
strates of CK2, may be a subject of such regulation, when
phosphorylation marks are established by default; removal
of these marks on the other hand may be a part of more con-
trolled processes.
The ﬁnal biological outcomes of impaired phosphorylation
levels of CTCF, including loss or gain of phosphorylation
site(s), may therefore trigger apoptosis or initiate uncontrolled
cellular growth and oncogenic activation. It is particularly
important in the view of the growing body of recent evidence
demonstrating the role of CK2 in proliferation, cell survival
and apoptosis ([22] and references therein). Given that CK2
A. El-Kady, E. Klenova / FEBS Letters 579 (2005) 1424–1434 1433levels are often elevated in cancers [22] it is tempting to specu-
late that overexpression of CK2 in cancer cells could lead to
excessive phosphorylation of CTCF, which may result in
non-controllable overproduction of c-myc and thus may be
one of the mechanisms of maintenance and evolution of tu-
mour cell population.
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